Skip to content
In deliveryUnited Kingdom

LIONNS-D2 Project - Production of T3S API, IMP and FDF

Published
Published 23 October 2025

Overview

Cardiff University's School of Medicine is procuring the manufacture of a novel investigational medicinal product (IMP), Triiodothyronine sulphate (T3S), for use in a Phase 2b clinical trial. The service includes the production of the active pharmaceutical ingredient (API), the IMP, and the finished drug formulation (FDF) in blister packs. This bespoke drug is intended for hypothyroid patients with a specific genetic variation affecting thyroid hormone metabolism. The supplier will manufacture the product to GMP standards, using a validated Route of Synthesis supported by existing preclinical and toxicology data.

Key details

Country
United Kingdom
Status
In delivery
Procedure
Direct
Published
23 October 2025

Award outcome

Awarded value
€953,600
Award date
21 October 2025
Contract period
6 November 2025 → 31 January 2027
Winner
  • Ardena Holding NV

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract

    24 October 2025

    View notice ↗
  2. Contract

    23 October 2025

    View notice ↗

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: LIONNS-D2 Project - Production of T3S API, IMP and FDF — won by Ardena Holding NV — Skim